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Association between leptin levels and
severity of suicidal behaviour in
schizophrenia spectrum disorders
Gohar SM, Dieset I, Steen NE, Mørch RH, Vedal TSJ, Reponen EJ,
Steen VM, Andreassen OA, Melle I. Association between leptin levels
and severity of suicidal behaviour in schizophrenia spectrum disorders.
Objective: Associations between suicidality and lipid dysregulation are
documented in mental illness, but the potential role of leptin remains unclear.
We examined the association between leptin and suicidal behaviour in
schizophrenia, together with the influence of other clinical and biological indices.
Method: We recruited a sample of 270 participants with schizophrenia
spectrum diagnoses. Blood samples were analysed for leptin, while
symptom severity was assessed by Positive and Negative Syndrome
Scale (PANSS) and Inventory of Depressive Symptomatology (IDS-C).
Patients’ history of suicidal behaviour was categorized into three
subgroups based on IDS-C suicide subscale: No suicidal behaviour,
mild/moderate suicidal behaviour and severe suicidal behaviour with/
without attempts.
Results: Mild/moderate suicidal behaviour was present in 17.4% and
severe suicidal behaviour in 34.8%. Both groups were significantly
associated with female gender (OR = 6.0, P = 0.004; OR = 5.9,
P = 0.001), lower leptin levels (OR = 0.4, P = 0.008; OR = 0.5,
P = 0.008) and more severe depression (OR = 1.2, P < 0.001;
OR = 1.1, P < 0.001) respectively. Smoking (OR = 2.6, P = 0.004),
younger age of onset (OR = 0.9, P = 0.003) and less use of leptin-
increasing medications (OR = 0.5, P = 0.031) were associated with
severe/attempts group, while higher C-reactive protein CRP (OR = 1.3,
P = 0.008) was associated with mild/moderate group.
Conclusion: Lower leptin levels were associated with higher severity of
suicidal behaviour in schizophrenia.
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Significant outcomes
• After adjusting for potential confounding factors (i.e. age, sex, BMI, smoking, and medications), the association
between leptin and severity of suicidal behaviour remained significant. The finding suggests potential biological
mechanisms in the development of suicidal behaviour that should be followed up in future studies.
• Increased risk of suicidal behaviour (both moderate and severe groups) was associated with female gender,
smoking, early age of onset and severe depression.
• Lower use of psychotropic medications that are known to increase leptin levels (i.e. clozapine, olanzapine, queti-
apine and mirtazapine) was associated with severe suicidal behaviour.
Limitations
• The study was observational with a cross-sectional design, and we can neither assume the direction of the associ-
ation between leptin and suicidal behaviour nor conclude regarding causality.
• The lack of a detailed psychometric test assessing suicidality prevents us from in-depth exploration of associa-
tions to other phenomena, such as the risk of violent suicide.
• We have not included a healthy control group since suicidal behaviour is sporadic in the healthy general popula-
tion.
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Patients with schizophrenia have significantly
higher mortality rates than the general population
(1), with a recent systematic review estimating an
average of 14.5 years of potential life lost (2). Life-
time suicide risk in schizophrenia is estimated to be
around 4.9% (3). The proportion of increased
mortality rates attributable to suicide, however,
varies across different studies, from 0% to 46% of
all causes of death (4). Since suicidal behaviour is
highly complex phenomenon, many studies have
investigated both clinical and biological risk fac-
tors for suicide in this patient group.
Interestingly, some clinical risk factors for sui-
cide were found to be disease-specific while others
were similar to those found in the general popula-
tion (5). The systematic review of Hor and Taylor
(6) identified 51 studies concerning risk of suicide
in schizophrenia published since 2004. The authors
highlighted several common and disease-specific
clinical factors with strong evidence of increased
risk, and these included depressive symptoms, the
presence of active positive symptoms, lower level
of negative symptoms, the presence of insight,
comorbid substance use, past individual and fam-
ily history of suicide.
Studies of potential biological risk factors for
suicide in general over the last two decades have
included investigations of the role of inflamma-
tory cytokines and lipid dysregulation. A recent
systematic review of 22 studies indicated that ele-
vated interleukin-6 (IL-6) and reduced IL-2 were
observed in patients with suicide attempts (7).
Wu and colleagues conducted a meta-analysis
including 65 studies, highlighting the potential
role of lipid dysregulation. The authors found
significantly lower serum levels of total choles-
terol (TC) and low-density lipoproteins (LDL) in
suicidal patients compared to non-suicidal
patients and healthy controls (8). These findings
highlight the possible underlying role of lipid dis-
turbances in the pathophysiology of suicide in
schizophrenia.
Leptin is a peptide hormone synthesized mainly
from adipose tissue. From its discovery by Zhang
and colleagues (9) in 1994, the effects of leptin on
the brain were initially seen as limited to the
homeostatic regulation of feeding and energy con-
sumption through its action on hypothalamus (10,
11). Recently, it has become clear that leptin has
many other brain regulatory functions that also
involve neuroendocrine, neuroinflammatory and
neurodevelopmental processes (12–14). These
functions are mainly mediated through the widely
distributed leptin receptors in the human brain,
located in the hypothalamic nuclei, hippocampus,
amygdala and cortex (15). Leptin receptors are
also present throughout the hypothalamic–pitu-
itary–adrenal (HPA) axis, an important area for
regulation of stress and emotional response (16).
Moreover, leptin has been hypothesized to exert
modulatory actions on both dopaminergic and
serotonergic systems (17, 18).
These emerging findings from preclinical studies
have encouraged research on potential links
between leptin dysregulation and clinical psy-
chopathology (19), including studies of the associa-
tion between serum leptin levels and symptom
profiles of schizophrenia. The results are however
conflicting. A few studies show that leptin levels
are increased, not only in patients using atypical
antipsychotics (20) but also in drug-free (21) and
drug naive subjects (22). However, another study
reported decreased leptin levels in patients with
schizophrenia, particularly in patients with severe
suicidal behaviour i.e. suicide attempts (23). The
role of leptin, a potential lipid-regulation asso-
ciated biomarker, has however been infrequently
investigated in suicide research.
Aims of the study
The current study has the primary aim to investi-
gate the association between leptin levels and suici-
dal behaviour in a representative clinical sample of
patients with schizophrenia spectrum disorders, to
test the hypothesis that lower levels of serum leptin
are associated with increased severity of suicidal
behaviour. A secondary aim is to assess other
potential clinical and biological indices that could




Subjects were recruited through the ongoing
Norwegian Thematically Organized Psychosis
(TOP) study. The project started in 2003 as a
multicentre study involving the major hospitals
of greater Oslo and is approved by the Regional
Committee for Medical Research Ethics. Inclu-
sion criteria are being 18–65 years of age, meet-
ing the diagnostic criteria for schizophrenia and
bipolar disorders according to Diagnostic and
Statistical Manual of Mental Disorders (DSM-
IV; American Psychiatric Association, 2000) and
being able and willing to give a written informed
consent to participate. Participants with a his-
tory of significant head injury, neurological
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disorder, mental retardation and autoimmune
disease were excluded.
For the present study, we included only subjects
with a diagnosis of schizophrenia and other psy-
chotic disorders diagnosed according to DSM-IV
with available serum leptin measurements. We
then excluded patients with C-reactive protein
(CRP) above 10 mg/L (n = 31) and with missing
data for the main research question of the study
(i.e. symptoms scales and information about suici-
dal behaviour) from the analyses. The final sample
consisted of 270 participants with the following
diagnostic distribution: schizophrenia (n = 145),
schizoaffective disorder (n = 43), schizophreniform
disorder (n = 13) and psychosis not otherwise
specified (NOS; n = 69).
Clinical variables
Sociodemographic and clinical data were collected
from clinical interviews and medical records. The
Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I) was used to confirm the diagno-
sis (24). We calculated duration of illness as the age
at time of the inclusion minus the age of onset of the
first psychotic episode. Standardized procedures
were used for physical examination that included
height, weight and body mass index (BMI). The fol-
lowing psychometric rating scales were used to
assess symptom severity: the Structured Interview
for the Positive and Negative Syndrome Scale
(PANSS) (25) and clinician-rated Inventory of
Depressive Symptomatology (IDS-C) (26). The
grouping of patients based on the severity of suici-
dal behaviour was derived from IDS-C item 18 on
suicide with the addition of information about a
history of at least one-lifetime suicidal attempt from
the clinical interviews and hospital records.
Item 18 of IDS-C measures suicidal severity
using a four-point scale (0–3). Here, (0) is scored
for those who do not think of suicide or death; (1)
is scored for those who feel that life is empty or is
not worth living; (2) is scored for those who thinks
of suicide/death several times in a week; and
finally, (3) is scored for those who thinks of sui-
cide/death several times a day, or has suicidal plans
or suicidal attempts. Based on this and lifetime his-
tory of attempts, we categorized the patients into
three subgroups: no suicidal behaviour (score = 0
on IDS-C/item 18 and no history of attempts),
mild to moderate suicidal behaviour (score from 1
to 2 on IDS-C/item 18 and no history of attempts)
and severe suicidal behaviour with or without
attempts (score = 3 on IDS-C/item 18 and at least
one history of attempt) henceforth ‘severe suicidal
behaviour’.
Biochemical variables
Fasting venous blood samples were obtained in the
morning. Measurement and analysis of total
cholesterol (TC), triglyceride (TG), low-density
lipoproteins (LDL) and standard C-reactive pro-
tein (CRP) were conducted at the Department of
Medical Biochemistry, Oslo University Hospital.
Leptin concentrations were measured using 125I-
labelled human leptin radioimmunoassay (HL-
81K Kit; EMD Millipore Corporation) and anal-
ysed at the Hormone Laboratory, Department of
Endocrinology, Aker University Hospital.
Medications
Studies have reported that psychotropic medica-
tions may increase leptin levels, in particular, olan-
zapine, clozapine, quetiapine and mirtazapine (27–
29). In order to adjust for potential confounding
effects of psychotropic medications in the statisti-
cal analysis, we used data from the clinical inter-
view and medical records together with
measurements of the serum level of different
antipsychotic drugs. Based on this, we dichoto-
mized the sample into two subgroups: the group
using psychotropic medications affecting leptin
(olanzapine, clozapine, quetiapine and mirtazap-
ine) vs. the group using other psychotropic medica-
tions/not using any psychotropic medications.
Statistical analysis
The data were analysed using the statistical pack-
age for Social Sciences (IBM Corp. IBM SPSS
Statistics for Windows, Version 24.0. Armonk,
NY: IBM Corp., 2016). The statistical significant
level was preset to P < 0.05 (two-tailed). Variables
were presented as numbers (percentages) or means
( standard deviation) as appropriate. Substitu-
tion with mean was used for missing data for
years of education (five patients missing this infor-
mation). Leptin levels were log-transformed for
all analyses due to markedly skewed distribution.
To investigate the association between leptin and
suicidal behaviour, with other sociodemographic,
clinical and biochemical characteristics, we started
out investigating their bivariate associations using
Pearson’s r for normally distributed continuous
variables as shown in Table 2. We then used mul-
tivariate multinomial logistic regression to esti-
mate the odds ratio (OR) of being in the mild to
moderate or the severe suicidal groups respec-
tively, compared to the no suicidality group. We
included all potential covariates with known clini-
cal associations to suicidal behaviour or to
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variation in leptin levels according to previous
studies, in addition to those showing significant
bivariate associations with both leptin and suici-
dal behaviour in our current sample. (i.e. age, gen-
der, daily tobacco smoking, BMI, age of onset,
medication affecting leptin, IDS – C total score
without suicide item 18 and CRP; Table 3). Lipid
measures (i.e. TC, TG and LDL) were not entered
into the multivariate analysis to avoid potential
multicollinearity issues since they were highly cor-
related with BMI and CRP. We then added (log)
leptin levels at the last step of the multivariate
analysis. To illustrate the distribution of (log) lep-
tin levels across groups, adjusted for covariates,
we used an analysis of covariance (ANCOVA) to
produce adjusted means for the error bar graph
shown in Fig. 1.
Results
Two hundred seventy patients with schizophrenia
spectrum disorders were participated, out of whom
161 (59.6%) were male. Mean age was 30.7
(10.1) and duration of illness was 8.2 (8.4)
years. Around half of the patients (52.2%) had
either mild or severe suicidal behaviour. Their
demographic, clinical and biochemical characteris-
tics are shown in Table 1.
In the bivariate analyses, we found serum leptin
levels to be positively and statistically significantly
correlated with female gender (r = 0.5, P < 0.001),
BMI (r = 0.5, P < 0.001), lipid levels [TC (r = 0.2,
P < 0.001); LDL (r = 0.2, P = 0.004); TG (r = 0.2,
P = 0.001)] and CRP (r = 0.4, P < 0.001). Severity
of suicidal behaviour was positively correlated
with female gender (r = 0.2, P = 0.011), daily
tobacco smoking (r = 0.2, P = 0.002), positive
symptoms (r = 0.2, P = 0.001), depression
(r = 0.3, P < 0.001), negatively correlated with age
of onset (r = 0.3, P < 0.001) and use of psy-
chotropic drugs that are known to increase leptin
level (r= 0.1, P= 0.019) (Table 2).
The multivariate multinomial logistic regression
analysis showed that female gender (OR = 6.00,
95% CI = 1.8–20.5; OR = 5.9, 95% CI = 2.2–16.0
respectively) and higher depressive symptoms
(OR = 1.2, 95% CI = 1.1–1.2; OR = 1.1, 95%
CI = 1.0–1.1 respectively) statistically significantly
increased the risk of being in the mild to moderate
or severe suicidal behaviour groups (compared to
the no suicidal behaviour group).
Importantly, lower levels of leptin also signifi-
cantly increased the risk of being in the mild to
moderate or severe suicidal behaviour groups
(OR = 0.4, 95% CI = 0.2–0.8; OR = 0.5, 95%
CI = 0.3–0.8 respectively). In addition, higher
CRP levels (OR = 1.3, 95% CI = 1.1–1.5)
increased the risk of being in the mild to moderate
suicidal behaviour group, while daily tobacco
smoking (OR = 2.6, 95% CI = 1.4–5.1), younger
age of onset (OR = 0.9, 95% CI = 0.9–1.0) and
less use of medications affecting leptin (i.e. clozap-
ine, olanzapine, quetiapine or mirtazapine;
OR = 0.5, 95% CI = 0.3–0.9) increased the risk of
Fig. 1. Error bar graph of adjusted leptin levels in relation to
severity of suicidal behaviour.
Table 1. Descriptive characteristics of the sample
N = 270
Age (years), M (SD) 30.7 (10.1)
Male sex, n (%) 161 (59.6)
Education (years), M (SD) 12.8 (2.9)
Caucasian ethnicity, n (%) 218 (80.7)
Daily tobacco smoking, n (%) 157 (58.1)
Age of onset (years), M (SD) 22.6 (8.6)




Psychosis NOS 69 (25.6)
Psychotropic medications, n (%)
Use on regular basis 328 (88.2)
Psychotropic medications affecting leptin* 141 (37.9)
PANSS – positive, M (SD) 15.1 (5.1)
PANSS – negative, M (SD) 15.8 (6.4)
IDS-C total, M (SD) 19.3 (12.6)
Suicidal behaviour†, n (%)
No 129 (47.8)
Mild to moderate 47 (17.4)
Severe with or without attempts 94 (34.8)
BMI (kg/m2), M (SD) 26.1 (5.1)
Total cholesterol (mmol/l), M (SD) 5.3 (1.1)
LDL (mmol/l), M (SD) 3.2 (1.0)
Triglyceride (mmol/l), M (SD) 1.5 (0.9)
Leptin‡(mg/l), M (SD) 6.3 (1.0)
CRP (mg/dl), M (SD) 3.3 (2.8)
BMI, body mass index; CRP, C-reactive protein; IDS-C, Inventory of Depressive
Symptomatology clinician-rated; LDL, low-density lipoproteins; M, mean; NOS, not
otherwise specified; PANSS, Positive and Negative Syndrome Scale; SD, standard
deviation.
*Psychotropic medications affecting leptin are clozapine, olanzapine, quetiapine and
mirtazapine.
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being in the severe suicidal behaviour group. The
pseudo-R2 (Cox and Snell) for the analysis was
0.38, and the detailed regression weights are found
in Table 3.
Finally, participants with both mild to moderate
and severe suicidal behaviour had significantly
lower adjusted levels of leptin compared to partici-
pants with no suicidal behaviour [F (2,
260) = 4.75, P = 0.009, partial g2 = 0.035].
Adjusted means and 95% CIs error bar of adjusted
leptin levels for the suicide severity groups are
shown in Fig. 1.
Discussion
The main finding of the current study is that lower
levels of leptin were associated with increased risk
of suicidal behaviour in schizophrenia spectrum
patients, also after adjusting for age, sex, smoking,
BMI and psychotropic medications affecting lep-
tin. This finding is in line with previous findings of
Atmaca and colleagues, who reported lower levels
of leptin in schizophrenia patients with suicidal
attempts, compared to patients without attempts
(23) and in patients with severe mental disorders
and suicide attempts compared to healthy controls
(30) respectively.
The contradictory findings concerning leptin
levels and suicidal behaviour in schizophrenia from
other previous studies could be explained by the
potential confounding influence of factors (i.e. age,
sex, BMI, dietary habits, smoking, age of onset
and duration of illness) that may act on leptin
levels in both mentally ill patients and healthy indi-
viduals (31–34). We here, however, found that
lower leptin levels were significantly associated
with moderate and severe suicidal behaviour (com-
pared to no suicidal behaviour) also after adjust-
ments for these factors.
A relationship between depression, suicidal
behaviour and low brain leptin has previously been
found in analyses of cerebral venous blood in
patients with major depressive disorders and
mRNA from post-mortem CNS tissue from
patients with completed suicide (35). Recent and
emerging evidence supports the notion that leptin
could be an essential component of the pathophys-
iology of depression and suicide (36). First, the
presence of leptin receptors in brain areas closely
related to depression neurobiology such as the
amygdala and the hippocampus, together with the
potential hippocampal synaptic neuroplasticity
induced by leptin documented in recent animal
studies, supports this hypothesis (37). Second, it
has been suggested that leptin has a modulatory
Table 2. Bivariate associations of leptin and suicide
Leptin† Suicidal behaviour‡
Age 0.1 0.1
Female sex 0.5** 0.2*
Daily tobacco smoking 0.1 0.2**
Medication affecting leptin§ 0.0 0.1*
BMI 0.5** 0.1
Age of onset 0.0 0.3**
PANSS – positive 0.1 0.2**
PANSS – negative 0.0 0.0





BMI, body mass index; CRP, C-reactive protein; IDS-C, Inventory of Depressive
Symptomatology clinician-rated; LDL, low-density lipoprotein; PANSS, Positive and
Negative Syndrome Scale; TC, total cholesterol; TG, triglyceride.
*P < 0.05, **P < 0.01
†log-transformed leptin score.
‡Suicidal behaviour is classified according to item 18 in IDS-C and lifetime history
of suicidal attempts.
§Psychotropic medications affecting leptin are clozapine, olanzapine, quetiapine
and mirtazapine.
¶IDS – C total score without suicidal ideation item 18.






Suicidal behaviour (mild to moderate) vs. None
Intercept 0.2 (1.7)
Age 0.0 (0.0) 0.7 1.0 0.9 1.0
Female sex 1.8 (0.68) 8.2** 6.0 1.8 20.5
Daily tobacco
smoking
0.2 (0.4) 0.1 1.2 0.5 2.8
BMI 0.0 (0.1) 0.6 1.1 0.9 1.2
Age of onset 0.0 (0.0) 0.1 1.0 1.0 1.1
Medication
affecting leptin
0.7 (0.4) 2.8 0.5 0.2 1.1
CRP 0.2 (0.1) 7.0** 1.3 1.1 1.5
IDS-C total (without
suicide item 18)
0.1 (0.0) 47.7** 1.2 1.1 1.2
Leptin 0.9 (0.4) 7.0** 0.4 0.2 0.8
Suicidal behaviour (severe and/or attempts) vs. None
Intercept 1.9 (1.3)
Age 0.0 (0.0) 0.1 1.0 1.0 1.1
Female sex 1.8 (0.5) 12.1** 5.9 2.2 16.0
Daily tobacco
smoking
1.0 (0.3) 8.1** 2.6 1.4 5.1
BMI 0.1 (0.1) 1.1 1.1 1.0 1.2
Age of onset 0.1 (0.0) 8.8** 0.9 0.9 1.0
Medication
affecting leptin
0.7 (0.3) 4.7* 0.5 0.3 0.9
CRP 0.1 (0.1) 1.2 1.1 0.9 1.2
IDS-C total (without
suicide item 18)
0.1 (0.0) 18.5** 1.1 1.0 1.1
Leptin 0.7 (0.3) 7.0** 0.5 0.3 0.8
R2 = 0.4 (Cox & Snell), 0.4 (Nagelkerke). Model v2 (18) = 127.2, P < 0.001
BMI, body mass index; CRP, C-reactive protein; IDS-C, Inventory of Depressive
Symptomatology clinician-rated.
*P < 0.05, **P < 0.01
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effect on HPA axis activity in the hypothalamus
and subsequently affect response to stress (16).
Third, evidence from animal studies shows a
potential modulatory role of leptin on serotonin
through its action on nitric oxide synthase (NOS)
and nitric oxide (NO) production, which could
affect serotonin reuptake (38) and activation (39).
In addition, NO levels are found to be high in
schizophrenia (40). The lack of inhibitory effects of
leptin on NO could aggravate the serotonin dys-
regulation in schizophrenia in turn affecting mood,
impulsivity and self-regulation. Thus, the seroton-
ergic pathway, in particular, could be considered
the main pathophysiological link between leptin,
mood, psychotic disorders and associated suicidal
behaviour (41).
Furthermore, the interaction between adiposity
and inflammation has been linked to leptin in
several studies on depression (42). Interestingly,
our finding supports this potential link and
extends it to suicidal behaviour. We found that
leptin levels were significantly positively corre-
lated with CRP and BMI, and that CRP was
associated with mild to moderate suicidal beha-
viour. The lack of any direct association between
suicidal behaviour and BMI in our sample could
be understood in terms of the recent findings of
population-based studies. These studies indicated
that suicidal behaviour is higher among under-
weight individuals (BMI < 20 kg/m2) and people
with extreme obesity (BMI ≥ 35 kg/m2) which
indicate a U-shaped or curvilinear relationship
(43, 44). This complex type of relationship is dif-
ficult to investigate in our sample, which mainly
comprised individuals with an average BMI with
a few overweight exceptions.
It is noteworthy that the use of specific psy-
chotropic medications (i.e. clozapine, olanzapine,
quetiapine and mirtazapine) could increase leptin
levels (28, 29). One of the interesting findings from
our analyses is that less use of these medications
was associated with severe suicidal behaviour.
Clozapine is the only antipsychotic drug that has
US Food and Drug Administration (FDA)
approval for treatment of suicidal behaviour (45),
at the same time as clozapine use is associated with
weight gain and increased leptin levels (46). This
finding raises the possibility of a potential patho-
physiological role of leptin in suicidal behaviour
processes, linked to other underlying mechanisms
such as adiposity and inflammation, which needs
further investigation.
Major strengths of this study include the well-
characterized and representative sample of
schizophrenia spectrum disorders patients,
together with the detailed clinical, biochemical and
medication records that allowed us to adjust for
potential confounders adequately. Major limita-
tions are the cross-sectional design that does not
allow us to conclude about the directionality of the
association between leptin and suicidality. More-
over, the lack of specific psychometric assessment
of suicidality and its related aspects prevent us
from exploring in-depth associations including the
use of violent means in attempts (30). Finally, we
did not include healthy controls in the current
study, as they have very low levels of suicidal beha-
viour and the main research question is targeting
the association between leptin levels and suicidal
behaviour.
In summary, this study indicates an inverse asso-
ciation between leptin and severity of suicidal
behaviour in schizophrenia. Proper assessment of
depression together with the use of psychotropic
drugs affecting leptin could have a beneficial role
in the management of suicide risk. Future studies
should explore the interaction between leptin and
inflammation, and its potential link to suicide, with
particular emphasis on the role of depressive symp-
tomatology. A better understanding of the com-
plex phenomenon of suicidal behaviour is essential
to improve prognosis and long-term outcome of
schizophrenia spectrum disorders.
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